Aliases & Classifications for Aging

MalaCards integrated aliases for Aging:

Name: Aging 56 74

External Ids:

OMIM 56 502000

Summaries for Aging

OMIM : 56 Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000)

MalaCards based summary : Aging is related to premature aging and hutchinson-gilford progeria syndrome. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Endometrial cancer and MAPK signaling pathway. The drugs Midazolam and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Senescence (/sɪˈnɛsəns/) or biological aging is the gradual deterioration of functional characteristics.... more...

Related Diseases for Aging

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 5809)
# Related Disease Score Top Affiliating Genes
1 premature aging 34.0 TP63 PDGFRB LMNA
2 hutchinson-gilford progeria syndrome 32.7 WRN TP53 SIRT3 LMNA
3 atypical werner syndrome 32.6 WRN LMNA
4 huntington disease 31.9 TP53 SOD1 SNCA PPARG AKT1
5 skin carcinoma 31.8 TP53 MAPK1 JUN AKT1
6 osteonecrosis 31.8 SERPINE1 PPARG HIF1A
7 medulloblastoma 31.8 WRN TP53 PDGFRB MAPK1 JUN HIF1A
8 kidney cancer 31.8 TP53 SERPINE1 MAPK1 HIF1A AKT1
9 varicocele 31.8 TP53 SOD1 HIF1A
10 pulmonary fibrosis, idiopathic 31.8 TP53 SERPINE1 MMP7 HIF1A AKT1
11 vascular disease 31.7 TP53 SOD1 SERPINE1 PPARG NAMPT MAPK1
12 osteoporosis 31.7 WRN TP53 SERPINE1 PPARG MAPK1 LMNA
13 acute promyelocytic leukemia 31.6 TP53 SERPINE1 PPARG MAPK1 JUN HIF1A
14 ewing sarcoma 31.6 TP53 PDGFRB MAPK1 HIF1A AKT1
15 kaposi sarcoma 31.6 TP53 MAPK1 JUN HIF1A AKT1
16 leukemia, acute myeloid 31.6 TP53 PDGFRB MAPK1 JUN HIF1A AKT1
17 fibrosarcoma 31.6 TP53 SERPINE1 MAPK1 JUN HIF1A
18 non-alcoholic fatty liver disease 31.6 SIRT3 SERPINE1 PPARG NAMPT JUN AKT1
19 endometrial cancer 31.4 TP53 PPARG MMP7 MAPK1 JUN HIF1A
20 neuroblastoma 31.3 TP53 SOD1 SNCA PPARG PDGFRB MAPK1
21 primary lateral sclerosis, adult, 1 31.3 SOD1 SNCA
22 microvascular complications of diabetes 5 31.3 SOD1 SERPINE1 HIF1A AKT1
23 hypertension, essential 31.1 TP53 SOD1 SIRT3 SERPINE1 PPARG NAMPT
24 alzheimer disease 31.1 TP53 SOD1 SNCA PPARG MAPK1 JUN
25 arteriosclerosis 31.0 SERPINE1 PPARG KL HIF1A
26 retinitis pigmentosa 30.8 TP53 SOD1 SNCA PPARG PDGFRB LMNA
27 peripheral nervous system disease 30.7 TP53 SOD1 SNCA LMNA AKT1
28 sleep apnea 30.7 SERPINE1 PPARG HIF1A
29 wilms tumor 1 30.6 TP63 TP53 KCNQ1DN AKT1
30 pancreatic cancer 30.6 TP53 PPARG PDGFRB MMP7 MAPK1 JUN
31 skin atrophy 30.5 WRN LMNA KL
32 hyperglycemia 30.5 SOD1 SERPINE1 PPARG NAMPT JUN HIF1A
33 overnutrition 30.5 SERPINE1 PPARG NAMPT AKT1
34 diabetes mellitus, noninsulin-dependent 30.5 WRN TP53 SOD1 SNCA SIRT3 SERPINE1
35 myocardial infarction 30.5 WRN TP53 SERPINE1 PPARG MMP7 HIF1A
36 gastric adenocarcinoma 30.4 TP53 PDGFRB MAPK1 JUN HIF1A AKT1
37 tuberous sclerosis 30.4 TP53 PDGFRB MAPK1 AKT1
38 sarcoma 30.4 TP53 PDGFRB MAPK1 JUN HIF1A AKT1
39 cardiovascular system disease 30.3 SOD1 SERPINE1 PPARG NAMPT AKT1
40 body mass index quantitative trait locus 11 30.2 TP53 SIRT3 SERPINE1 PPARG NAMPT LMNA
41 glioblastoma multiforme 30.2 TP53 PPARG PDGFRB MAPK1 JUN HIF1A
42 breast adenocarcinoma 30.2 TP53 SERPINE1 MAPK1 AKT1
43 renal cell carcinoma, nonpapillary 30.2 TP53 SNCA PDGFRB MMP7 JUN HIF1A
44 cholangiocarcinoma 30.2 TP53 MMP7 MAPK1 AKT1
45 cervical cancer 30.1 TP63 TP53 MMP7 MAPK1 JUN HIF1A
46 pneumoconiosis 30.1 SOD1 SERPINE1 JUN
47 diabetes mellitus 30.0 WRN TP53 SOD1 SIRT3 SERPINE1 PPARG
48 breast fibroadenoma 30.0 TP63 TP53 HIF1A
49 bladder urothelial carcinoma 30.0 TP53 SERPINE1 MMP7 HIF1A AKT1
50 estrogen-receptor positive breast cancer 29.9 TP53 HIF1A AKT1

Graphical network of the top 20 diseases related to Aging:



Diseases related to Aging

Symptoms & Phenotypes for Aging

Clinical features from OMIM:

502000

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.09 MAPK1
2 Decreased viability GR00055-A-2 10.09 MAPK1
3 Decreased viability GR00221-A-1 10.09 AKT1 MAPK1 PDGFRB PPARG
4 Decreased viability GR00221-A-2 10.09 AKT1 PPARG SOD1 JUN
5 Decreased viability GR00221-A-3 10.09 AKT1 MAPK1 PDGFRB PPARG SOD1 JUN
6 Decreased viability GR00221-A-4 10.09 AKT1 MAPK1 PDGFRB PPARG SOD1
7 Decreased viability GR00249-S 10.09 AKT1 MAPK1 SOD1 JUN
8 Decreased viability GR00342-S-1 10.09 MAPK1 PDGFRB
9 Decreased viability GR00342-S-2 10.09 MAPK1
10 Decreased viability GR00342-S-3 10.09 MAPK1
11 Decreased viability GR00386-A-1 10.09 PPARG JUN

MGI Mouse Phenotypes related to Aging:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.57 AKT1 HIF1A JUN KL LMNA MAPK1
2 cellular MP:0005384 10.54 AKT1 HIF1A JUN KL LMNA MAPK1
3 growth/size/body region MP:0005378 10.53 AKT1 HIF1A JUN KL LMNA MAPK1
4 homeostasis/metabolism MP:0005376 10.5 AKT1 HIF1A JUN KL LMNA MAPK1
5 behavior/neurological MP:0005386 10.47 AKT1 HIF1A JUN KL LMNA MAPK1
6 immune system MP:0005387 10.47 AKT1 HIF1A JUN KL LMNA MAPK1
7 endocrine/exocrine gland MP:0005379 10.43 AKT1 HIF1A JUN KL LMNA MAPK1
8 integument MP:0010771 10.43 AKT1 HIF1A JUN KL LMNA MAPK1
9 mortality/aging MP:0010768 10.43 AKT1 HIF1A JUN KL LMNA MAPK1
10 hematopoietic system MP:0005397 10.4 AKT1 HIF1A JUN KL LMNA MAPK1
11 adipose tissue MP:0005375 10.33 AKT1 KL LMNA PDGFRB PPARG RGN
12 digestive/alimentary MP:0005381 10.3 HIF1A KL LMNA MAPK1 MMP7 PDGFRB
13 liver/biliary system MP:0005370 10.27 AKT1 HIF1A JUN KL LMNA MAPK1
14 embryo MP:0005380 10.24 AKT1 HIF1A JUN MAPK1 NAMPT PDGFRB
15 nervous system MP:0003631 10.22 AKT1 HIF1A JUN KL LMNA MAPK1
16 craniofacial MP:0005382 10.21 HIF1A KL LMNA MAPK1 PDGFRB TP53
17 muscle MP:0005369 10.16 AKT1 HIF1A KL LMNA MAPK1 PDGFRB
18 neoplasm MP:0002006 10.13 AKT1 HIF1A MAPK1 MMP7 PPARG SERPINE1
19 hearing/vestibular/ear MP:0005377 10.11 KL LMNA MAPK1 PPARG RGN SOD1
20 limbs/digits/tail MP:0005371 10.11 HIF1A KL LMNA PDGFRB RGN TP53
21 normal MP:0002873 10.07 AKT1 HIF1A JUN LMNA PDGFRB PPARG
22 reproductive system MP:0005389 10 AKT1 KL LMNA MAPK1 PDGFRB PPARG
23 renal/urinary system MP:0005367 9.97 HIF1A KL LMNA PDGFRB PPARG SERPINE1
24 respiratory system MP:0005388 9.85 AKT1 HIF1A JUN KL LMNA MAPK1
25 skeleton MP:0005390 9.83 AKT1 HIF1A JUN KL LMNA MAPK1
26 vision/eye MP:0005391 9.47 HIF1A JUN KL LMNA MAPK1 MMP7

Drugs & Therapeutics for Aging

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 891)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
3
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
6
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
7
Cisatracurium Approved Phase 4 96946-41-7
8
Pantoprazole Approved Phase 4 102625-70-7 4679
9
Rilpivirine Approved Phase 4 500287-72-9
10
Ticlopidine Approved Phase 4 55142-85-3 5472
11
Ramipril Approved Phase 4 87333-19-5 5362129
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13
Polyestradiol phosphate Approved Phase 4 28014-46-2
14
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
15
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
16
Phylloquinone Approved, Investigational Phase 4 84-80-0
17
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
18
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
19
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
20
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
21
Enalaprilat Approved Phase 4 76420-72-9 6917719
22
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
23
Rivaroxaban Approved Phase 4 366789-02-8
24
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
25
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
26
Menthol Approved Phase 4 2216-51-5 16666
27
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
28
Hydralazine Approved Phase 4 86-54-4 3637
29
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
30
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
31
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
32
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
33
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
34
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
35
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
36
Simvastatin Approved Phase 4 79902-63-9 54454
37
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
38
Doxazosin Approved Phase 4 74191-85-8 3157
39
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
40
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
41
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
42
Atenolol Approved Phase 4 29122-68-7 2249
43
Indapamide Approved Phase 4 26807-65-8 3702
44
Spirapril Approved Phase 4 83647-97-6 5311447
45
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
46
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
47
Desflurane Approved Phase 4 57041-67-5 42113
48
Mirabegron Approved Phase 4 223673-61-8 9865528
49
Dalteparin Approved Phase 4 9005-49-6
50
Amlodipine Approved Phase 4 88150-42-9 2162

Interventional clinical trials:

(show top 50) (show all 3936)
# Name Status NCT ID Phase Drugs
1 Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly Unknown status NCT00966199 Phase 4 anti-hypertensive medication
2 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
3 A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging Unknown status NCT03465202 Phase 4 Capecitabine
4 Outcome Comparison Between PFNA and InterTAN in Intertrochanteric Fractures Unknown status NCT01797237 Phase 4
5 The Effect of Dexmedetomidine on Postoperative Recovery in Elderly Patients With Femoral Neck Fracture Undergoing Hip Hemi-arthroplasty Unknown status NCT01934049 Phase 4 Total Intravenous Anesthesia and Peripheral nerve blocks
6 Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users Unknown status NCT02945293 Phase 4
7 Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
8 Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients Unknown status NCT02301676 Phase 4 Sevoflurane;propofol
9 An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
10 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
11 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
12 Treatment of Intertrochanteric Fracture With New Type of Intramedullary Nail Unknown status NCT01437176 Phase 4
13 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
14 The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery Unknown status NCT02503826 Phase 4 Sufentanil;Sufentanil;Sufentanil;Midazolam;propofol;cisatracurium
15 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
16 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
17 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
18 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
19 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
20 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
21 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
22 Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial Unknown status NCT02967029 Phase 4 Esmolol Hydrochloride;Remifentanil Hydrochloride
23 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
24 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
25 Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney. Unknown status NCT01208714 Phase 4 Optimal medical therapy
26 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
27 Discovery of Effects of Retinol on Human Skin Aging in Individuals of East Asian Descent Completed NCT02906566 Phase 4 Retinol;Placebo
28 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
29 Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly Completed NCT00018356 Phase 4 testosterone
30 Genomic Outcomes of Metformin Completed NCT02986659 Phase 4 Metformin;Placebo
31 Multi-parameter Immune Profile Associated With the Humoral Response to Influenza Vaccine, Vaxigrip® in Healthy and Frail Elderly Subjects Aged 65-90 Years in Singapore Completed NCT03266237 Phase 4 Vaxigrip®
32 hCG Priming Prior to COH in Poor Responder IVF Patients Completed NCT00870025 Phase 4
33 Aging White Matter Changes, Executive Dysfunction and Depression Completed NCT00918684 Phase 4 Escitalopram
34 The Effects of Pectin on Aging-related Changes in Intestinal Barrier Function, Immune Function and Microbial Composition Completed NCT02376270 Phase 4
35 Single Cell Molecular Analysis of Influenza Vaccine Induced T Cell Responses in Adults 65 Years of Age or Older Completed NCT04077424 Phase 4
36 Canadian Study of the Use of Injectable POLY-L-LACTIC Acid (Sculptra Therapy) in Aesthetic Medicine Completed NCT00447551 Phase 4 Poly-L-Lactic Acid
37 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines Completed NCT00856414 Phase 4
38 A Comparative Randomized Double-Blinded Study of the Effect of Dysport and Botox on Forehead Wrinkles and EMG Activity Completed NCT00434863 Phase 4 botulinum toxin type A
39 Volume Restoration of the Aging Midface With Sculptra Aesthetic Completed NCT01307865 Phase 4 injectable poly-L-lactic acid
40 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Center Study on the Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women. Completed NCT01598272 Phase 4
41 Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules Completed NCT02765763 Phase 4 2-Minute Reveal Masque;24/7 Barrier Repair Cream;8-in-1 BioSerum;Null Formula 2-Minute Reveal Masque;Null Formula 24/7 Barrier Repair Cream;Null Formula 8-in-1 BioSerum
42 Immunogenicity of Pneumococcal Vaccination and Revaccination in Older Adults Completed NCT00239694 Phase 4
43 Split-face Study of Changing in Skin Physiology and Clinical Appearance After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces Completed NCT02312154 Phase 4
44 Randomized, Controlled, Multi-Centered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic) for Improving Facial Wrinkles and Skin Quality Completed NCT02003833 Phase 4
45 Oral Administration of L-Arginine in Patients With Erectile Dysfunction Completed NCT00777075 Phase 4 L-arginine;Placebo
46 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Completed NCT01869634 Phase 4 darunavir with ritonavir and fixed-dose viread+emtricitabine daily
47 3% Dihydroxyacetone (DHA or Sunless Tanning Agent) Inhibits Vitamin D Production in the Skin in Response to Ultraviolet Light Completed NCT00818467 Phase 4
48 A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4 Memantine;Placebo
49 Comparison of Clinical Outcome Parameters, the Patient Benefit Index (PBI) and Patient Satisfaction After Ablative Fractional Laser Treatment of Peri-orbital Rhytides Completed NCT00994474 Phase 4
50 A Prospective, Open Label, Randomized, Comparative, Split-Face Study Evaluating Reconstituted JUVÉDERM® Ultra Injectable Gel Versus COSMODERM® 1 Human Based Collagen Implant for the Treatment of Vertical Lip Rhytids and Radial Cheek Lines Completed NCT01212809 Phase 4

Search NIH Clinical Center for Aging

Genetic Tests for Aging

Anatomical Context for Aging

MalaCards organs/tissues related to Aging:

40
Brain, Skin, Heart, Bone, Skeletal Muscle, Kidney, Testes

Publications for Aging

Articles related to Aging:

(show top 50) (show all 30015)
# Title Authors PMID Year
1
Lamin A-dependent nuclear defects in human aging. 56 61
16645051 2006
2
Genome dynamics in aging mice. 56 61
12421760 2002
3
Mitochondrial genetics: a paradigm for aging and degenerative diseases? 56 61
1533953 1992
4
Short telomeres are sufficient to cause the degenerative defects associated with aging. 56
19944403 2009
5
Increased cell-to-cell variation in gene expression in ageing mouse heart. 56
16791200 2006
6
Gene regulation and DNA damage in the ageing human brain. 56
15190254 2004
7
Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes. 56
12538859 2003
8
Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. 56
12483296 2003
9
Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. 56
11274426 2001
10
Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine. 56
10900004 2000
11
Role of nuclear background and in vivo environment in variable segregation behavior of the aging-dependent T414G mutation at critical control site for human fibroblast mtDNA replication. 56
15328912 1999
12
Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. 56
10531063 1999
13
Mitochondrial genotype associated with longevity. 56
9449878 1998
14
Growing old: the most common mitochondrial disease of all? 56
1303273 1992
15
Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. 56
1303287 1992
16
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. 56
1303288 1992
17
Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. 56
1463763 1992
18
Evidence for and against the causal involvement of mitochondrial DNA mutation in mammalian ageing. 56
1383763 1992
19
Strength and aging resistance of monolithic zirconia: an update to current knowledge. 61
31768195 2020
20
Aging of starting solutions for nanoparticles synthesis with two different ultrasonication. 61
32361276 2020
21
Involvement of protein S-nitrosylation in regulating beef apoptosis during postmortem aging. 61
32413758 2020
22
Silica infiltration in partially stabilized zirconia: Effect of hydrothermal aging on mechanical properties. 61
32347214 2020
23
Effect of hydrothermal aging on the properties of zirconia with different levels of translucency. 61
32543411 2020
24
Analysis of free aniline in chrome-free leather accelerated aging. 61
32408227 2020
25
The influence of probiotics on bile acids in diseases and aging. 61
32504921 2020
26
Potential health effects of dietary nitrate supplementation in aging and chronic degenerative disease. 61
32294579 2020
27
Response of tungsten (W) solubility and chemical fractionation to changes in soil pH and soil aging. 61
32413664 2020
28
Dataset of quantitative proteomic analysis to understand aging processes in rabbit liver. 61
32490075 2020
29
Effects of polymer aging on sorption of 2,2',4,4'-tetrabromodiphenyl ether by polystyrene microplastics. 61
32289606 2020
30
The long-term environmental risks from the aging of organochlorine pesticide lindane. 61
32416373 2020
31
MRI-based biomarkers of accelerated aging and dementia risk in midlife: how close are we? 61
32325150 2020
32
Nrf2 knockout dysregulates iron metabolism and increases the hemolysis through ROS in aging mice. 61
32450168 2020
33
The emerging role of T follicular helper (TFH) cells in aging: Influence on the immune frailty. 61
32344191 2020
34
Sleep, Noninvasive Brain Stimulation, and the Aging Brain: Challenges and Opportunities. 61
32380212 2020
35
Cognitive processes in aging effects on attentional alerting. 61
32380362 2020
36
Traditional fermented foods with anti-aging effect: A concentric review. 61
32517898 2020
37
Antioxidant and anti-aging activities of polysaccharides from Cordyceps cicadae. 61
32339570 2020
38
The effects of environmental stressors on candidate aging associated genes. 61
32344118 2020
39
Aging indicators for stored carioca beans. 61
32517899 2020
40
Wnt signaling pathway in aging-related tissue fibrosis and therapies. 61
32272170 2020
41
Fracture force of CAD/CAM resin composite crowns after in vitro aging. 61
31712983 2020
42
Multiple MuSK signaling pathways and the aging neuromuscular junction. 61
32353380 2020
43
Role of microRNAs in neurodegeneration induced by environmental neurotoxicants and aging. 61
32283224 2020
44
Aging Affects Fine and Coarse Coding of Orientation Information in Macaque Primary Visual Cortex. 61
32407975 2020
45
Aging Equines: Understanding the Experience of Caring for a Geriatric Horse with a Chronic Condition. 61
32534771 2020
46
Senescent Cells: Emerging Targets for Human Aging and Age-Related Diseases. 61
32531228 2020
47
Circadian glucocorticoid oscillations preserve a population of adult hippocampal neural stem cells in the aging brain. 61
31222184 2020
48
Aortic remodeling is modest and sex-independent in mice when hypertension is superimposed on aging. 61
32068640 2020
49
Anti-aging properties of Dendrobium nobile Lindl.: From molecular mechanisms to potential treatments. 61
32268205 2020
50
Next Steps Toward AMH as a Robust Biomarker for Assessing Ovarian Aging in Individual Women. 61
32315387 2020

Variations for Aging

Expression for Aging

Search GEO for disease gene expression data for Aging.

Pathways for Aging

Pathways related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.89 TP53 PPARG PDGFRB MAPK1 JUN AKT1
2 12.79 TP53 PDGFRB MAPK1 JUN AKT1
3
Show member pathways
12.76 TP53 PDGFRB MAPK1 KL AKT1
4
Show member pathways
12.71 TP53 PDGFRB MAPK1 JUN AKT1
5
Show member pathways
12.7 TP63 TP53 MAPK1 LMNA JUN AKT1
6 12.7 TP53 PPARG PDGFRB MAPK1 JUN HIF1A
7
Show member pathways
12.63 TP53 SIRT3 PDGFRB MAPK1 JUN AKT1
8
Show member pathways
12.58 TP53 PDGFRB MAPK1 JUN HIF1A AKT1
9
Show member pathways
12.47 TP53 PDGFRB JUN AKT1
10 12.45 TP53 MMP7 MAPK1 JUN AKT1
11 12.42 TP53 MAPK1 JUN AKT1
12
Show member pathways
12.42 PDGFRB MAPK1 JUN HIF1A AKT1
13
Show member pathways
12.35 TP53 MAPK1 JUN AKT1
14
Show member pathways
12.35 PPARG PDGFRB MAPK1 AKT1
15 12.34 TP53 MMP7 MAPK1 JUN AKT1
16 12.33 TP53 MAPK1 HIF1A AKT1
18
Show member pathways
12.26 TP53 PDGFRB MAPK1 LMNA AKT1
19
Show member pathways
12.23 TP53 SIRT3 MAPK1 HIF1A AKT1
20 12.22 TP53 MMP7 MAPK1 AKT1
21
Show member pathways
12.21 TP53 PPARG JUN AKT1
22 12.19 TP53 SERPINE1 MAPK1 AKT1
23 12.18 TP53 MAPK1 JUN AKT1
24
Show member pathways
12.17 TP53 MAPK1 JUN AKT1
25
Show member pathways
12.16 PDGFRB MAPK1 JUN AKT1
26
Show member pathways
12.11 TP53 MAPK1 JUN AKT1
27 12.1 TP53 MAPK1 JUN AKT1
28 12.09 TP63 TP53 SERPINE1 JUN
29 12.07 PPARG MAPK1 JUN AKT1
30
Show member pathways
12.07 TP53 SOD1 PPARG KL AKT1
31 12.05 TP53 MAPK1 HIF1A AKT1
32
Show member pathways
12.02 PDGFRB MAPK1 JUN AKT1
33
Show member pathways
12.02 TP53 SERPINE1 PPARG MAPK1 JUN HIF1A
34 12.01 TP53 MAPK1 JUN AKT1
35 11.99 TP53 PDGFRB MAPK1 AKT1
36 11.98 SERPINE1 MAPK1 HIF1A AKT1
37 11.96 TP53 SERPINE1 MAPK1 JUN
38 11.93 SERPINE1 MAPK1 JUN AKT1
39 11.9 PPARG MAPK1 JUN AKT1
40 11.89 SERPINE1 PPARG NAMPT LMNA HIF1A
41 11.87 PDGFRB MMP7 HIF1A
42
Show member pathways
11.85 MAPK1 JUN AKT1
43 11.84 TP63 TP53 AKT1
44
Show member pathways
11.83 MAPK1 JUN AKT1
45 11.81 TP53 MAPK1 JUN
46
Show member pathways
11.81 PDGFRB MAPK1 JUN AKT1
47 11.8 TP53 MAPK1 JUN AKT1
48 11.79 SERPINE1 JUN AKT1
49 11.77 TP53 MAPK1 AKT1
50 11.74 TP53 JUN HIF1A

GO Terms for Aging

Cellular components related to Aging according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 WRN TP63 TP53 SOD1 SIRT3 PPARG
2 nucleus GO:0005634 9.83 WRN TP63 TP53 SOD1 SNCA SIRT3
3 protein-containing complex GO:0032991 9.28 TP63 TP53 SOD1 SNCA SIRT3 PPARG

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 TP63 TP53 SERPINE1 PPARG NAMPT JUN
2 positive regulation of gene expression GO:0010628 10.07 TP53 MAPK1 LMNA HIF1A AKT1
3 response to drug GO:0042493 10 TP53 SOD1 SNCA PPARG JUN
4 positive regulation of transcription, DNA-templated GO:0045893 9.98 TP63 TP53 PPARG MAPK1 JUN HIF1A
5 negative regulation of neuron apoptotic process GO:0043524 9.92 SOD1 SNCA JUN HIF1A
6 cellular response to hypoxia GO:0071456 9.89 TP53 LMNA HIF1A AKT1
7 regulation of signal transduction by p53 class mediator GO:1901796 9.88 WRN TP63 TP53 AKT1
8 response to oxidative stress GO:0006979 9.88 WRN TP53 SOD1 AKT1
9 response to organic cyclic compound GO:0014070 9.87 PPARG PDGFRB NAMPT JUN
10 insulin receptor signaling pathway GO:0008286 9.86 NAMPT KL AKT1
11 protein import into nucleus GO:0006606 9.85 TP53 LMNA AKT1
12 negative regulation of protein kinase activity GO:0006469 9.85 SNCA RGN AKT1
13 positive regulation of endothelial cell proliferation GO:0001938 9.84 JUN HIF1A AKT1
14 response to nutrient levels GO:0031667 9.83 SOD1 PPARG MMP7
15 response to estrogen GO:0043627 9.81 PPARG PDGFRB MAPK1
16 response to hydrogen peroxide GO:0042542 9.81 SOD1 PDGFRB JUN
17 response to organic substance GO:0010033 9.81 SOD1 PPARG JUN AKT1
18 circadian rhythm GO:0007623 9.8 TP53 SERPINE1 NAMPT JUN
19 positive regulation of apoptotic process GO:0043065 9.8 TP53 SOD1 SNCA PPARG PDGFRB JUN
20 cellular response to reactive oxygen species GO:0034614 9.78 MAPK1 JUN AKT1
21 microglial cell activation GO:0001774 9.73 SNCA NAMPT JUN
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 PDGFRB NAMPT JUN AKT1
23 replicative senescence GO:0090399 9.68 TP53 SERPINE1
24 negative regulation of telomerase activity GO:0051974 9.67 TP53 PPARG
25 positive regulation of glucose metabolic process GO:0010907 9.67 RGN AKT1
26 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.67 TP53 PPARG JUN HIF1A
27 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.66 MAPK1 AKT1
28 response to fluid shear stress GO:0034405 9.65 PDGFRB AKT1
29 retina vasculature development in camera-type eye GO:0061298 9.65 PDGFRB HIF1A
30 negative regulation of reactive oxygen species metabolic process GO:2000378 9.65 TP53 SIRT3 HIF1A
31 peripheral nervous system myelin maintenance GO:0032287 9.64 SOD1 AKT1
32 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.63 TP53 HIF1A
33 protein tetramerization GO:0051262 9.63 TP63 TP53 SNCA
34 replicative cell aging GO:0001302 9.62 WRN TP63
35 cellular response to cadmium ion GO:0071276 9.62 SOD1 MAPK1 JUN AKT1
36 positive regulation of superoxide dismutase activity GO:1901671 9.61 SIRT3 RGN
37 negative regulation of apoptotic process GO:0043066 9.56 TP53 SOD1 SNCA RGN PDGFRB JUN
38 positive regulation of cell aging GO:0090343 9.54 TP53 LMNA
39 regulation of thymocyte apoptotic process GO:0070243 9.52 TP53 HIF1A
40 cell aging GO:0007569 9.46 WRN TP63 TP53 SOD1
41 aging GO:0007568 9.44 WRN TP63 SOD1 SNCA SIRT3 RGN

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.92 TP53 PDGFRB MAPK1 HIF1A AKT1
2 chromatin binding GO:0003682 9.91 WRN TP63 TP53 PPARG JUN
3 transcription factor binding GO:0008134 9.8 TP53 PPARG MAPK1 JUN HIF1A
4 zinc ion binding GO:0008270 9.8 TP53 SOD1 SNCA SIRT3 RGN PPARG
5 transcription regulatory region sequence-specific DNA binding GO:0000976 9.77 TP63 TP53 SNCA PPARG JUN
6 p53 binding GO:0002039 9.65 TP63 TP53 HIF1A
7 double-stranded DNA binding GO:0003690 9.62 TP63 PPARG MAPK1 JUN
8 copper ion binding GO:0005507 9.61 TP53 SOD1 SNCA
9 identical protein binding GO:0042802 9.61 TP63 TP53 SOD1 SNCA PPARG NAMPT
10 transcription regulatory region DNA binding GO:0044212 9.55 TP63 TP53 SNCA PPARG JUN
11 MDM2/MDM4 family protein binding GO:0097371 9.49 TP63 TP53
12 arachidonic acid binding GO:0050544 9.46 SNCA PPARG
13 enzyme binding GO:0019899 9.28 TP53 SOD1 SNCA SIRT3 PPARG PDGFRB

Sources for Aging

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....